Page 43 – Clinical Laboratory int.

GenNext and Agilent combine technologies to enhance structural biology analysis

, 7 November 2024/in E-News /by panglobal

A novel integration of protein footprinting and ion mobility mass spectrometry technologies promises to accelerate structural biology research in the biopharmaceutical sector, following a collaboration announced by GenNext Technologies and Agilent.

Antiverse secures £3.5m to advance AI-driven antibody design platform

, 7 November 2024/in E-News /by panglobal

The Cardiff-based antibody design company Antiverse has secured £3.5 million in additional seed funding, bringing their total equity financing to £7.2 million. The investment round, spearheaded by i&i Biotech Fund I and Kadmos Capital, saw participation from existing investors including InnoSpark Ventures, UKI2S, Tensor Ventures, and AngelHub.

Hoxb8 MAT improves diagnosis of peanut allergy

, 7 November 2024/in Featured Articles, Autoimmunity & Allergy /by panglobal

A recent report published by the Food Standards Agency in the UK [Patterns and prevalence of adult food allergy (PAFA); https://shorturl.at/jnaLY] estimates that around 6% of the UK adult population have a clinically confirmed IgE-mediated food allergy.

Weighted analysis of autoantibodies in new classification criteria for antiphospholipid syndrome

, 7 November 2024/in Featured Articles, Autoimmunity & Allergy /by panglobal

By Dr Jacqueline Gosink New American College of Rheumatology and European Alliance of Associations for Rheumatology classification criteria for antiphospholipid syndrome have been developed to aid cohort selection for research and clinical trials. The classification system includes both clinical and laboratory criteria, which are hierarchically clustered, weighted and risk-stratified to ensure high specificity.

Causes of congenital neutropenia and challenges of diagnosis

, 7 November 2024/in Hematology & Flow Cytometry, Featured Articles /by panglobal

The congenital neutropenia syndromes are rare conditions caused by mutations in genes associated with various cell processes. While their clinical presentations may overlap, their natural histories vary. Accurate diagnosis of the genetic etiology of specific conditions is crucial for providing individually tailored management, as the different syndromes have different risk profiles for progression to bone […]

Mapping, monitoring and surveillance of Tropical and Neglected Diseases

, 7 November 2024/in Featured Articles, Rapid Tests & POC /by panglobal

Tropical infectious diseases such as malaria, cholera, yellow fever, and Dengue affect more than 2 billion people worldwide. Also included in this list are the so-called “Neglected Tropical Diseases” or NTD’s, a sub-group of mainly infectious diseases that occur against a background of extreme poverty. The WHO lists 17 priority Neglected Tropical Diseases, among them […]

Development of rapid and POC tests for viral diagnostics

, 6 November 2024/in Featured Articles, Rapid Tests & POC /by panglobal

It is often said that “necessity is the mother of invention”, something that often seems to happen in war situations. The COVID-19 pandemic, in many ways, felt like a war, and drove fast changes in behaviour, very quickly having us all performing lateral flow tests at home, in a way that could not have been […]

Axol Bioscience strengthens disease modelling capabilities with strategic Phenocell acquisition

, 6 November 2024/in E-News /by panglobal

In a significant move to enhance its induced pluripotent stem cell (iPSC) technology portfolio, Axol Bioscience has announced the complete acquisition of French biotechnology firm Phenocell SAS, marking a strategic expansion into ophthalmology and dermatology research models.